Pharmacologic management of heart failure among older adults by office- based physicians in the United States

Journal of Family Practice

Volumn 44, Issue 4, 1997, Pages 382-390

  Croft, Janet B ^a,b   Giles, Wayne H ^a   Roegner, Russell H ^a   Anda, Robert F ^a   Casper, Michele L ^a   Livengood, John R ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Aged; angiotensin converting enzyme inhibitors; antihypertensive agents; epidemiology; heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; METOLAZONE; MINOXIDIL; NITRATE; PHENTOLAMINE; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CLINICAL PRACTICE; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; HEALTH SURVEY; HEART FAILURE; HUMAN; HYPERTENSION; MALE; MEDICAL EDUCATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; DIGITALIS GLYCOSIDES; DIURETICS; DRUG UTILIZATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; OFFICE VISITS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030898406     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. May DS, Kelly JJ, Mendlein JM, Garbe PL. Surveillance of major causes of hospitalization among the elderly, 1988. In: CDC surveillance summaries, April 1991. MMWR 1991; 40(no. SS-1):7-21.
2. Parmley WW. Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 1989; 13:771-85.
3. Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990; 4:3068-75.
4. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995; 155:829-37.
5. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice? JAMA 1995; 273:1436-8.
6. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M (for the Cardiovascular Health Study Collaborative Research Group). Assessing the use of medications in the elderly: methods and initial experience in the cardiovascular health study. J Clin Epidemiol 1992; 45:683-92.
7. Glynn RJ, Brock DB, Harris T, et al. Use of antihypertensive drugs and trends in blood pressure in the elderly. Arch Intern Med 1995; 155:1855-60.
8. Hlatky MA, Cotugno HE, Mark DB, O'Connor C, Califf RM, Pryor DB. Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. Am J Cardiol 1988; 61: 515-18.
9. Pashos CL, Normand ST, Garfinkle JB, Newhouse JP, Epstein AM, McNeil BJ. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. J Am Coll Cardiol 1994; 23:1023-30.
10. Pilote L, Califf RM, Sapp S, et al. Regional variation across the United States in the management of acute myocardial infarction. N Engl J Med 1995; 333:565-72.
11. Chatterjee K. Heart failure therapy in evolution [editorial]. Circulation 1996; 94:2689-93.
12. Groden DL. Vasodilator therapy for congestive heart failure: lessons from mortality trials. Arch Intern Med 1993; 153:445-54.
13. Hlatky MA, Fleg JL, Hinton PC, et al. Physician practice in the management of congestive heart failure. J Am Coll Cardiol 1986; 8:966-70.
14. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1994; 88:2941-52.
15. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994; 271:1276-80.
16. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314:1547-52.
17. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
19. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-10.
20. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared to placebo. Circulation 1990; 82:774-80.
21. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336:1-6.
22. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325:1468-75.
23. Bryant E, Shimizu I. Sample design, sampling variance, and estimation procedures for the National Ambulatory Medical Care Survey. National Center for Health Statistics, Vital and Health Statistics 1988, series 2, No. 108. DHHS publication No. (PHS) 88-1382.
24. Schappert SM. National Ambulatory Medical Care Survey, 1991 summary. Vital and Health Statistics 1994, series 13, No. 116. DHHS publication No. (PHS) 94-1777.
25. Schappert SM. National Ambulatory Medical Care Survey, 1992 summary. Advance data from Vital and Health Statistics, No. 253. Hyattsville, Md: National Center for Health Statistics, 1994. DHHS publication No. (PHS) 95-1885.
26. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273:214-19.
27. Food and Drug Administration. National drug code directory, 1982 edition. Washington, DC: Public Health Service, 1982.
28. Konstam MA, Dracup K, Baker DW, et al. Heart failure: evaluation and care of patients with left-ventricular systolic dysfunction. Clinical practice guideline No. 11. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, June 1994. AHCPR publication No. 94-0612.
29. Public Health Service and Health Care Financing Administration. International classification of diseases, ninth revision, clinical modification. Washington, DC: Public Health Service, 1980.
30. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure. I. Pharmacologic treatment. JAMA 1994; 272: 1361-6.
31. ACC/AHA task force report: guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee on evaluation and management of heart failure). J Am Coll Cardiol 1995; 26:1376-98.
32. Braunwald E. Heart failure. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS. Harrison's principles of internal medicine, 11th ed. New York, NY: McGraw-ffill, 1987:905-16.
33. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148:1023-38.
34. Alderman MH. Which antihypertensive drugs first - and why! JAMA 1992; 267:2786-7.
35. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-83.
36. Croft JB, Giles WH, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997. In press.
37. Oka RK, Stotts NA, Dae MW, Haskell WL, Gortner SR. Daily physical activity levels in congestive heart failure. Am J Cardiol 1993; 71:921-5.
38. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993; 22(suppl A):198A-200A.
39. Failure to treat heart failure [editorial]. Lancet 1992; 339:278-9.
40. Packer M, Lee WH, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986; 315:847-53.
41. Cleland JGF, Dargie HJ, McAlpine H, et al. Severe hypotension after first dose enalapril in heart failure. Br Med J 1985; 291:1309-12.
42. Broadhead WE, Larson DB, Yarnall KSH, Blazer DG, Tse C-KJ. Tricyclic antidepressant prescribing for nonpsychiatric disorders: an analysis based on data from the 1985 National Ambulatory Medical Care Survey. J Fam Pract 1991; 33:24-32.
43. Hohmann AA, Larson DB, Thompson JW, Beardsley RS. Psychotropic medication prescription in US ambulatory care. DICP Ann Pharmacother 1991; 25:85-9.
44. Pippalla RS, Riley DA, Chinburapa V. Influencing the prescribing behaviour of physicians: a meta-evaluation. J Clin Pharm Ther 1995; 20:189-98.